Drugs / AI-09
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05565950 | Sep 2022 → Jun 2024 | — | Eirion Therapeutics Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07321834 | Dec 2025 → Feb 2026 overdue | — | Eirion Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AI-09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565950 ↗ |
| Modality | Protein / enzyme biologic | “Botulinum toxin, Type A” NCT05565950 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT05565950 ↗ |